Review Article | Published:

Testosterone deficiency, insulin resistance and the metabolic syndrome

Nature Reviews Endocrinology volume 5, pages 673681 (2009) | Download Citation

Subjects

Abstract

Changing lifestyles and an excess of food supply in developed countries have resulted in an increasing prevalence of overweight and obesity. As a consequence, a disorder of complex pathophysiology involving visceral adipose tissue as an endocrine organ, dyslipidemia, insulin resistance and hypertension has emerged—the so-called metabolic syndrome. This disorder can lead to the manifestation of type 2 diabetes mellitus and cardiovascular disease. In men, testosterone deficiency may contribute to the development of the metabolic syndrome. In turn, states of hyperinsulinemia and obesity lead to a reduction of testicular testosterone production. Testosterone has reciprocal effects on the generation of muscle and visceral adipose tissue by influencing the commitment of pluripotent stem cells and by inhibiting the development of preadipocytes. Insulin sensitivity of muscle cells is increased by augmenting mitochondrial capacity and fostering expression of oxidative phosphorylation genes. Testosterone has a protective effect on pancreatic β cells, which is possibly exerted by androgen-receptor-mediated mechanisms and influence of inflammatory cytokines. As some, but not all, epidemiological and interventional studies indicate, testosterone substitution might be helpful in preventing or attenuating the metabolic syndrome in aging men with late-onset hypogonadism and in hypogonadal patients with type 2 diabetes mellitus, but larger controlled trials are needed to confirm such hypotheses.

Key points

  • Testosterone exerts fundamental effects on various elements of body composition and metabolism

  • Testosterone deficiency is associated with an increased prevalence of components of the metabolic syndrome, especially accumulation of visceral adipose tissue and insulin resistance

  • The adverse metabolic state and factors or hormones secreted by visceral adipose tissue contribute to the generation of hypogonadism

  • Studies suggest that testosterone substitution weakens the close relation between testosterone deficiency and insulin resistance and the metabolic syndrome, but more clinical evidence is needed to confirm these findings

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683–689 (2001).

  2. 2.

    , , , & Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 27, 2676–2681 (2004).

  3. 3.

    et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int. J. Obesity Relat. Metab. Disord. 25, 1782–1788 (2001).

  4. 4.

    Secular trends in variables associated with the metabolic syndrome of North American children and adolescents: a review and synthesis. Am. J. Hum. Biol. 15, 786–794 (2003).

  5. 5.

    et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 53, 2087–2094 (2004).

  6. 6.

    & The metabolic syndrome: risk factors and management. J. Cardiovasc. Nurs. 21, 306–313 (2006).

  7. 7.

    & Lower endogenous androgens predict central adiposity in men. Ann. Epidemiol. 2, 675–682 (1992).

  8. 8.

    , , , & Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J. Clin. Endocrinol. Metab. 85, 3276–3282 (2000).

  9. 9.

    & Androgens and abdominal obesity. Baillieres Clin. Endocrinol. Metab. 12, 441–451 (1998).

  10. 10.

    , , & Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men. Diabetologia 46, 31–39 (2003).

  11. 11.

    , & Association of specific symptoms and metabolic risks with serum testosterone in older men. J. Clin. Endocrinol. Metab. 91, 4335–4343 (2006).

  12. 12.

    , , & Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur. J. Endocrinol. 159, 739–746 (2008).

  13. 13.

    , & Insulin sensitivity during combined androgen blockade for prostate cancer. J. Clin. Endocrinol. Metab. 91, 1305–1308 (2006).

  14. 14.

    , , , & Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106, 581–588 (2006).

  15. 15.

    , & Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448–4456 (2006).

  16. 16.

    et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28, 1636–1642 (2005).

  17. 17.

    Expert Panel on Detection Evaluation, Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).

  18. 18.

    World Health Organization. Definition and Classification of Diabetes Mellitus and its Complications Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus World Health Organization [], (1999).

  19. 19.

    et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237–252 (2003).

  20. 20.

    , & Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med. 23, 469–480 (2006).

  21. 21.

    , , , & Endogenous sex hormones and metabolic syndrome in aging men. J. Clin. Endocrinol. Metab. 90, 2618–2623 (2005).

  22. 22.

    et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27, 1036–1041 (2004).

  23. 23.

    et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J. Clin. Endocrinol. Metab. 91, 843–850 (2006).

  24. 24.

    et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int. J. Impot. Res. 21, 1–8 (2009).

  25. 25.

    , , & Low serum testosterone and mortality in male veterans. Arch. Intern. Med. 166, 1660–1665 (2006).

  26. 26.

    , & Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. 93, 68–75 (2008).

  27. 27.

    et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J. Clin. Endocrinol. Metab. 90, 712–719 (2005).

  28. 28.

    et al. The metabolic syndrome is frequent in Klinefelter's syndrome and is associated with abdominal obesity and hypogonadism. Diabetes Care 29, 1591–1598 (2006).

  29. 29.

    , , , & Metabolic syndrome in men with Klinefelter's syndrome. Urology 71, 1109–1113 (2008).

  30. 30.

    , , & Morbidity in Klinefelter syndrome: a Danish register study based on hospital discharge diagnoses. J. Clin. Endocrinol. Metab. 91, 1254–1260 (2006).

  31. 31.

    et al. Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. Clin. Endocrinol. (Oxf.) 69, 785–791 (2008).

  32. 32.

    , , & Increased mortality in Klinefelter syndrome. J. Clin. Endocrinol. Metab. 89, 3830–3834 (2004).

  33. 33.

    , , , & Insulin resistance in patients with Klinefelter's syndrome and idiopathic gonadotropin deficiency. J. Formos. Med. Assoc. 97, 534–540 (1998).

  34. 34.

    et al. Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 92, 4254–4259 (2007).

  35. 35.

    et al. Lower sex hormone-binding globulin is more strongly associated with the metabolic syndrome than lower total testosterone in older men: the Health in Men Study. Eur. J. Endocrinol. 158, 785–792 (2008).

  36. 36.

    & in Testosterone: Action, Deficiency, Substitution 3rd edn (eds Nieschlag, E. & Behre, H. M.) 93–124 (Cambridge University Press, Cambridge, 2004).

  37. 37.

    Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat. Clin. Pract. Urol. 4, 161–166 (2007).

  38. 38.

    , , , & Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77–79 (1991).

  39. 39.

    & Diabetes mellitus during the course of familial progressive muscular atrophy; incidental association or metabolic manifestation of the myopathy [Italian]. Arch. Pathol. Clin. Med. 34, 335–342 (1957).

  40. 40.

    , & Neurologic course, endocrine dysfunction and triplet repeat size in spinal bulbar muscular atrophy. Can. J. Neurol. Sci. 31, 378–382 (2004).

  41. 41.

    et al. Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp. Clin. Endocrinol. Diabetes 107, 522–529 (1999).

  42. 42.

    et al. Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J. Clin. Endocrinol. Metab. 90, 2636–2641 (2005).

  43. 43.

    Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 5, 551–559 (2002).

  44. 44.

    Adipose tissue hormones. J. Endocrinol. Invest. 25, 855–861 (2002).

  45. 45.

    et al. Signals from intra-abdominal fat modulate insulin and leptin sensitivity through different mechanisms: neuronal involvement in food-intake regulation. Cell. Metab. 3, 223–229 (2006).

  46. 46.

    , , , & Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144, 5081–5088 (2003).

  47. 47.

    et al. Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147, 141–154 (2006).

  48. 48.

    , & Testosterone increases lipolysis and the number of beta-adrenoreceptors in male rat adipocytes. Endocrinology. 128, 379–382 (1991).

  49. 49.

    , & Androgens and body fat distribution. J. Steroid Biochem. Mol. Biol. 108, 272–280 (2008).

  50. 50.

    , , , & Effects of testosterone on insulin receptor substrate-1 and glucose transporter 4 expression in cells sensitive to insulin [Chinese]. Zhonghua Yi Xue Za Zhi 86, 1474–1477 (2006).

  51. 51.

    et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

  52. 52.

    , & Strong association between serum levels of leptin and testosterone in men. Clin. Endocrinol. (Oxf.) 47, 237–240 (1997).

  53. 53.

    et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2510–2513 (1997).

  54. 54.

    , , & Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: results of a cross-sectional study. Eur. J. Endocrinol. 146, 505–511 (2002).

  55. 55.

    & Direct effects of sex steroid hormones on adipose tissues and obesity. Obes. Rev. 5, 197–216 (2004).

  56. 56.

    et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J. Clin. Endocrinol. Metab. 84, 3673–3680 (1999).

  57. 57.

    et al. Leptin and aging: correlation with endocrine changes in male and female healthy adult populations of different body weights. J. Clin. Endocrinol. Metab. 85, 1954–1962 (2000).

  58. 58.

    et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology 140, 4939–4947 (1999).

  59. 59.

    et al. Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men. J. Clin. Endocrinol. Metab. 93, 784–791 (2008).

  60. 60.

    et al. KiSS-1/kisspeptins and the metabolic control of reproduction: physiologic roles and putative physiopathological implications. Peptides 30, 139–145 (2009).

  61. 61.

    et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J. Clin. Endocrinol. Metab. 89, 5462–5468 (2004).

  62. 62.

    et al. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr. Mol. Med. 8, 816–828 (2008).

  63. 63.

    & Inflammation and atherosclerosis. Herz 29, 741–748 (2004).

  64. 64.

    et al. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation 110, 3604–3609 (2004).

  65. 65.

    et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 101, 2149–2153 (2000).

  66. 66.

    et al. In the elderly, interleukin-6 plasma levels and the 174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 22, 2066–2071 (2002).

  67. 67.

    , , & C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109, 1349–1353 (2004).

  68. 68.

    & Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu. Rev. Med. 51, 245–270 (2000).

  69. 69.

    et al. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J. Gerontol. A Biol. Sci. Med. Sci. 54, M434–M439 (1999).

  70. 70.

    et al. Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines. Clin. Transplant. 14, 218–225 (2000).

  71. 71.

    , & The anti-androgen hydroxyflutamide and androgens inhibit interleukin-6 production by an androgen-responsive human osteoblastic cell line. J. Bone Miner. Res. 14, 1330–1337 (1999).

  72. 72.

    et al. Tumor necrosis factor-alpha and interleukin-1beta increase the Fas-mediated apoptosis of human osteoblasts. J. Lab. Clin. Med. 134, 222–231 (1999).

  73. 73.

    Possible involvement of cytokines in diffuse intravascular coagulation and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. 12, 343–359 (1999).

  74. 74.

    , & Endothelial preconditioning by transient oxidative stress reduces inflammatory responses of cultured endothelial cells to TNF-alpha. FASEB J. 14, 555–564 (2000).

  75. 75.

    , & Influence of cytokines and growth factors on distinct steroidogenic enzymes in vitro: a short tabular data collection. Ann. NY Acad. Sci. 966, 166–186 (2002).

  76. 76.

    et al. Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha. Mol. Cell. Biol. 24, 2593–2604 (2004).

  77. 77.

    , , , A & Dose-dependent effects of recombinant human interleukin-6 on the pituitary-testicular axis. J. Interferon Cytokine Res. 19, 1271–1276 (1999).

  78. 78.

    , , & Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 42, 303–307 (1993).

  79. 79.

    & Testosterone suppresses the response of the hypothalamic-pituitary-adrenal axis to interleukin-6. Neuroimmunomodulation 8, 39–44 (2000).

  80. 80.

    et al. Sex hormones modulate inflammatory mediators produced by macrophages. Ann. NY Acad. Sci. 876, 426–429 (1999).

  81. 81.

    et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 89, 3313–3318 (2004).

  82. 82.

    , , , & Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm. Metab. Res. 39, 366–371 (2007).

  83. 83.

    et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type 2 diabetic men with partial androgen deficiency. J. Endocrinol. 189, 595–604 (2006).

  84. 84.

    et al. Gonadotropin treatment restores in vitro interleukin-1beta and tumour necrosis factor-alpha production by stimulated peripheral blood mononuclear cells from patients with idiopathic hypogonadotropic hypogonadism. Clin. Exp. Immunol. 132, 265–270 (2003).

  85. 85.

    , , & Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J. Clin. Endocrinol. Metab. 90, 6603–6608 (2005).

  86. 86.

    , , , & The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 156, 595–602 (2007).

  87. 87.

    & Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab. Syndr. Relat. Disord. 6, 87–102 (2008).

  88. 88.

    , , & Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy. Clin. Endocrinol. (Oxf.) 60, 500–507 (2004).

  89. 89.

    et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348, 593–600 (2003).

  90. 90.

    et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol. 45, 1441–1448 (2005).

  91. 91.

    , & Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men. J. Appl. Physiol. 102, 847–852 (2007).

  92. 92.

    et al. Impaired endothelial progenitor cell function predicts age-dependent carotid intimal thickening. Basic Res. Cardiol. 103, 582–586 (2008).

  93. 93.

    et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J. Clin. Endocrinol. Metab. 91, 4599–4602 (2006).

  94. 94.

    et al. Androgens stimulate endothelial progenitor cells through an androgen receptor-mediated pathway. Clin. Endocrinol. (Oxf.) 68, 284–289 (2008).

  95. 95.

    et al. Androgen treatment of abdominally obese men. Obes. Res. 1, 245–251 (1993).

  96. 96.

    et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 24, 2149–2151 (2001).

  97. 97.

    , & Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 6, 1–7 (2003).

  98. 98.

    , , & Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 154, 899–906 (2006).

  99. 99.

    et al. Dose-dependent effects of testosterone on regional adipose tissue distribution in healthy young men. J. Clin. Endocrinol. Metab. 89, 718–726 (2004).

  100. 100.

    , , , & Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J. Clin. Endocrinol. Metab. 93, 139–146 (2008).

  101. 101.

    et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int. J. Impot. Res. 20, 378–387 (2008).

  102. 102.

    et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 299, 39–52 (2008).

  103. 103.

    , , & Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 41, 7–13 (2009).

  104. 104.

    et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J. Androl. 30, 1–9 (2009).

Download references

Author information

Affiliations

  1. Center of Reproductive Medicine and Andrology, WHO Collaboration Center for Male Reproduction, Münster, Germany.

    • Michael Zitzmann

Authors

  1. Search for Michael Zitzmann in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Michael Zitzmann.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrendo.2009.212

Further reading